Takeda Pharmaceutical Co Ltd

Takeda launches low‑IgA, ready‑to‑use GAMMAGARD LIQUID ERC in the U.S. to streamline PI therapy, cut admin costs, and outpace competitors with a strong IP moat.

Takeda Pharmaceutical’s 2026 analyst outlook: a Hold rating amid steady growth, solid capital, and a diversified oncology‑CNS portfolio that keeps investors watching Japan’s pharma scene.

Takeda’s strong oncology pipeline and AI‑powered drug‑development tools are boosting analyst confidence and positioning the company for growth in Japan and global markets.

Takeda’s Phase 3 win for oral psoriasis drug zasocitinib offers a safe, effective, cost‑efficient option poised to reshape the competitive, reimbursement‑driven dermatology market.

Takeda’s 52‑week VERIFY study shows rusfertide safely reduces phlebotomy in polycythemia vera, offering durable efficacy and a strong commercial case for market access.

Takeda’s 52‑week rusfertide study shows 83 % hematocrit control and low thrombotic risk, while its multibillion‑dollar Innovent partnership targets next‑gen immuno‑oncology therapies.

Takeda’s shares edge toward a historic peak as investors eye its strong oncology, GI and CNS pipeline, with promising Phase‑III data and upcoming regulatory approvals driving confidence.

Takeda Pharmaceutical Co. Ltd. has formed a strategic alliance with Innovent Biologics to co-develop and commercialize several late-stage investigational agents, expanding its oncology portfolio and positioning the company to capture a larger share …

Takeda Pharmaceutical Co Ltd has announced significant progress in its cancer treatments, including reimbursement of its cancer drug FRUZAQLA in Quebec and advancements in γδ T cell cancer treatments.

Takeda Pharmaceutical’s cancer drug FRUZAQLA has been publicly reimbursed for treating metastatic colorectal cancer in Quebec, following positive recommendations from Canadian health agencies.